RLYB
RLYB
NASDAQ · Biotechnology

Rallybio Corp

$4.75
+0.10 (+2.12%)
As of Feb 8, 2:05 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 116.64M 118.58M 115.83M
Net Income -21,434,773 -22,545,743 -15,491,219
EPS
Profit Margin -18.4% -19.0% -13.4%
Rev Growth -8.2% -9.4% -4.9%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 64.35M 70.31M 72.54M
Total Equity 151.82M 147.11M 145.93M
D/E Ratio 0.42 0.48 0.50
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -23,823,087 -23,688,809 -21,137,696
Free Cash Flow -12,084,786 -12,382,292 -11,826,701